Angelini Pharma Company

Media

Angelini Pharma Company
  • Home
  • About Us
  • About Epilepsy
  • Media
    • Press Release
  • Contact
  • News + Press Releases
  • 2021
  • 2020
  • 2019

New study demonstrates the safety and tolerability of treatment with cenobamate tablets in adults with focal seizures

The results of the long-term, open-label extension (OLE) of a randomized, double-blind, placebo-controlled study of cenobamate (C013) have been…

Read more July 26, 2021

Angelini Pharma finalizes the acquisition agreement

• Through this acquisition, Angelini Pharma will be a major player in the market of companies focused on the treatment of central nervous system…

Press Release February 2, 2021

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*

Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping…

Press Release January 29, 2021

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments

Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million…

Press Release January 4, 2021

Related Articles


  • The Lancet Neurology

    November 13, 2019
    Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published
  • Bioworld

    November 4, 2019
    Arvelle’s CEO Mark Altmeyer Interview
Angelini Pharma Company
+41 (0) 417115882 info.ch@angelinipharma.com
LinkedIn LinkedIn Twitter Twitter
  • Home
  • Privacy Policy
Manage Cookie Consent
We use cookies to optimise your experience and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}